Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 6,680,000 shares, a decline of 30.4% from the December 31st total of 9,600,000 shares. Approximately 12.6% of the shares of the company are sold short. Based on an average trading volume of 1,750,000 shares, the days-to-cover ratio is currently 3.8 days.

Ventyx Biosciences Stock Performance

VTYX stock traded down $0.05 during trading on Tuesday, hitting $1.83. 1,295,095 shares of the company's stock traded hands, compared to its average volume of 1,843,217. The stock has a market capitalization of $129.05 million, a price-to-earnings ratio of -0.77 and a beta of 0.53. Ventyx Biosciences has a 52 week low of $1.67 and a 52 week high of $11.48. The business has a fifty day simple moving average of $2.31 and a 200 day simple moving average of $2.24.

Insider Activity at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan purchased 261,752 shares of the business's stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares of the company's stock, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sheila Gujrathi acquired 130,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now directly owns 130,000 shares of the company's stock, valued at approximately $300,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 630,000 shares of company stock worth $1,262,415. 18.18% of the stock is owned by company insiders.

Institutional Trading of Ventyx Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. bought a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $60,000. Cubist Systematic Strategies LLC grew its position in Ventyx Biosciences by 165.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company's stock valued at $345,000 after acquiring an additional 93,247 shares during the last quarter. Squarepoint Ops LLC increased its stake in Ventyx Biosciences by 101.3% in the second quarter. Squarepoint Ops LLC now owns 76,539 shares of the company's stock worth $177,000 after purchasing an additional 38,524 shares during the period. AQR Capital Management LLC bought a new stake in shares of Ventyx Biosciences during the second quarter worth $131,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock worth $56,000 after purchasing an additional 7,096 shares during the last quarter. Hedge funds and other institutional investors own 97.88% of the company's stock.

Wall Street Analyst Weigh In

VTYX has been the subject of several research analyst reports. HC Wainwright reaffirmed a "neutral" rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. Oppenheimer restated an "outperform" rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.